A Study of BGB-11417 in Participants With Myeloid Malignancies

Recruiting

Phase 1

Phase 2

BGB-11417A Study of BGB-11417 in Participants With Myeloid Malignancies

Sponsor:

BeiGene

Code:

NCT04771130

Conditions

Acute Myeloid Leukemia

Myelodysplastic Syndromes

Myelodysplastic/Myeloproliferative Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BGB-11417

Azacitidine

Posaconazole

BGB-11417

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-23. This information was provided to ClinicalTrials.gov by BeiGene on 2025-09-22.